Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer

Journal of Obstetrics and Gynaecology Research

Volumn 32, Issue 3, 2006, Pages 309-314

  Nakae, Mitsuhiro ^b   Iwamoto, Ichiro ^a,b   Fujino, Toshinori ^a   Maehata, Yoshiyasu ^b   Togami, Shin Ichi ^b   Yoshinaga, Mitsuhiro ^b   Douchi, Tsutomu ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cancer; Osteopontin; Ovary

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; OSTEOPONTIN;

ARTICLE; ASCITES; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; MIDDLE AGED; OSTEOPONTIN; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744460515     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2006.00403.x     Document Type: Article

References (20)

1. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005 58 : 308 312.
2. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001 30 : 670 675.
3. Moch H, Schraml P, Bubendorf L et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999 154 : 979 980.
4. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998 4 : 844 847.
5. Cooper BC, Ritchie JM, Broghammer CLW et al. Preoperative serum vascular endothelial growth factor level: Signjficance in ovarian cancer. Clin Cancer Res 2002 8 : 3193 3197.
6. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002 287 : 1671 1679.
7. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 1985 232 : 715 724.
8. Ohmori R, Momiyama Y, Taniguci H et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 2003 170 : 333 337.
9. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995 760 : 109 126.
10. Tamura A, Shingai M, Aso N, Hazuku T, Nasu M. Osteopontin is released from the heart into the coronary circulation in patients with a previous anterior wall myocardial infarction. Circ J 2003 67 : 742 744.
11. Le QT, Sutphin PD, Raychaudhuri S et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinoma. Clin Cancer Res 2003 9 : 59 67.
12. Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997 3 : 605 611.
13. Agrawal D, Chen T, Irby R et al. Osteopontin identified as colon cancer tumor progression marker. C R Biol 2003 326 : 1041 1043.
14. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993 7 : 1475 1482.
15. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002 95 : 506 512.
16. Schorge JO, Drake RD, Lee H et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004 10 : 3474 3478.
17. Brakora KA, Lee H, Yusuf R et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004 93 : 361 365.
18. Tiniakos DG, Yu H, Liapis H. Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum Pathol 1998 29 : 1250 1254.
19. Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating facto using mixtures of multivariate normal distributions. J Clin Oncol 2004 22 : 4059 4066.
20. Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005 102 : 7677 7682.